It is made available under a CC-BY-NC-ND 4.0 International license .

1 Iron biomarkers predict peripheral artery disease in females: a cross-sectional

- 2 analysis of HEIST-DiC and NHANES participants
- 3
- 4 Anand Ruban Agarvas^{1,2}, Stefan Kopf^{1,3,4}, Tiago J.S. Lopes^{1,2,10}, Paul Thalmann^{1,5}, José
- 5 Manuel Fernández-Real⁶, Peter Nawroth^{1,3}, *Martina U. Muckenthaler^{1,2,7,8,9}
- 6
- 7 Affiliations
- ⁸ ¹Heidelberg University, Heidelberg, Germany.
- 9 ²Center For Translational Biomedical Iron Research, Department of Pediatric Hematology,
- 10 Oncology Immunology and Pulmonology, University Hospital Heidelberg, Heidelberg, 11 Germany.
- ³Clinic for Endocrinology, Diabetology, Metabolic Diseases and Clinical Chemistry (Internal
 Medicine 1), University Hospital Heidelberg, Heidelberg, Germany.
- ⁴German Center of Diabetes Research (DZD), Neuherberg, Germany.
- ¹⁵ ⁵Institute of Medical Biometry, University Hospital Heidelberg, Heidelberg, Germany.
- 16 ⁶Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de
- Girona (IdIBGi), CIBEROBN (CB06/03/010) and Instituto de Salud Carlos III (ISCIII), Girona
 17007, Spain.
- ¹⁹ ⁷Molecular Medicine Partnership Unit, Heidelberg, Germany.
- ⁸Translational Lung Research Center Heidelberg (TLRC), German Center for Lung
 Research (DZL), Heidelberg, Germany.
- ⁹German Centre for Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim,
 Germany.
- ¹⁰Nezu Life Sciences, Karlsruhe, Germany
- 25
- 26 *Corresponding author
- 27
- 28

29 Address for correspondence

- 30 Department of Pediatric Hematology, Oncology and Immunology, Heidelberg University,
- 31 Heidelberg, Germany.
- 32 Tel.: +496221566923; Fax: +496221564580. E-mail: martina.muckenthaler@med.uni-
- 33 heidelberg.de (M.U. Muckenthaler).

It is made available under a CC-BY-NC-ND 4.0 International license .

34 Abstract

35

36 Background

37 Iron overload has been proposed as a risk factor for atherosclerosis but the available data

38 are controversial. Here we investigated whether iron biomarkers within physiological limits

39 that frequently differ between sexes are associated with peripheral arterial disease (PAD)

40

41 Methods

Using two different analytical approaches (machine-learning and logistic regression), we studied the association between blood iron biomarkers and PAD in 368 individuals from the Heidelberg Study on Diabetes and Complications (HEIST-DiC) and in 5101 individuals from the National Health and Nutrition Examination Survey (NHANES 1999-2004).

46

47 Results

48 We found that iron biomarkers were among the top predictors of PAD in the machine-49 learning classification in both cohorts. In the HEIST-DiC cohort, ferritin, iron, and transferrin 50 were ranked among the top predictive markers, while in the NHANES cohort ferritin, total 51 iron binding capacity (TIBC), transferrin saturation (TSAT) and iron showed high predictive 52 power. In the regression analysis ferritin showed a positive interaction among females in the 53 HEIST-DiC (OR 2.68, 95% CI 0.94-7.61, p=0.057) and NHANES cohorts (OR 1.76, 95% CI 54 1.16-2.67, p=0.008). The multivariable regression analysis of the NHANES cohort, detected a nonlinear relationship between ferritin and PAD in that certain ferritin ranges (48-97 ng/mL: 55 56 OR 14.59, 95% CI 1.6-135.93, p= 0.019; 98-169 ng/mL: OR 171.07, 95% CI 1.27-23404, p= 57 0.039) in females associated positively with PAD.

58

59 Conclusion

Taken together our data show that iron biomarkers, importantly, elevated ferritin is associated with clinically apparent PAD in females. These findings add to the body of evidence suggesting sex differences in PAD and highlight a possible role of iron (directly or indirectly) in this relationship.

64

65 Keywords

Iron, Vascular Diseases, Arterial Occlusive Diseases, Atherosclerosis, Peripheral ArterialDisease

It is made available under a CC-BY-NC-ND 4.0 International license .

68 Introduction

Peripheral arterial disease (PAD) is a common atherosclerotic vascular disorder of the arteries of the lower limbs that affects millions of individuals worldwide^{1,2}. Compared to cardiovascular and cerebrovascular disease, PAD is less well studied, and our understanding of the disease process is still poor. The known risk factors of PAD include old age, smoking, and comorbidities such as diabetes, hypertension or Vitamin D excess¹.

74

75 Iron is an essential micronutrient, however, its accumulation in excess contributes to the 76 generation of reactive oxygen species. Various regulatory systems maintain iron homeostasis by controlling absorption, transport, and storage³. Under physiological 77 conditions, iron is bound to transferrin in the plasma, and transported to cells that require 78 79 iron. Usually, less than one-third of transferrin's binding sites are occupied by iron, allowing 80 free iron entering the circulation to be efficiently sequestered. However, in pathological 81 states associated with iron overload, the binding capacity of transferrin is nearly saturated 82 resulting in the appearance of 'non-transferrin-bound iron (NTBI)'. Therefore, iron overload is discussed as a risk factor for the development of atherosclerosis⁴. Accordingly, inhibition of 83 84 ferroptosis, an iron-dependent form of cell death, has been shown to protect from atherosclerosis⁵. Iron and PAD may be linked by sex hormones. Changes in estrogen and 85 progesterone levels associated with menopause were shown to impair endothelial function, 86 especially among women^{6,7}. Both hormones further control hepcidin, the master regulator of 87 88 iron homeostasis in opposing directions, with estrogen⁸ inhibiting and progesterone⁹ 89 activating hepcidin expression.

90

91 In our previous work, we demonstrated that iron overload in mouse models and humans with 92 hemochromatosis show an aggravation of atherosclerosis and vessel damage, respectively¹⁰. Specifically, we found that NTBI in the circulation contributes to 93 atherosclerosis by oxidising low-density lipoproteins (LDL) and by inducing vascular 94 dysfunction; in addition, iron deposition in the vasculature of hemochromatotic mice was 95 associated with more severe atherosclerosis¹⁰. Whether or not iron levels within 96 97 physiological limits affect atherogenesis is currently unclear and available data are controversial. Most studies undertaken so far have investigated the relationships between 98 iron-related parameters [e.g. plasma iron, ferritin, transferrin, transferrin saturation (TSAT)] 99 and cardiovascular disease^{11–17} but associations with PAD are rarely addressed. 100

101

102 To address this, we analyzed iron biomarkers for their associations with PAD and by 103 considering sex-specific differences. We used two different datasets and orthogonal 104 approaches: 1) machine learning (ML) classification and 2) logistic regression. Both methods

It is made available under a CC-BY-NC-ND 4.0 International license .

105 can be used for analyzing relationships between variables, but they differ in their approach 106 and application. ML classification tasks can analyze complex patterns in multidimensional 107 data and identify nonlinear interactions among variables. They are particularly useful when 108 manual specification of relationships is challenging as is the case for human clinical data. In 109 contrast, regression analysis quantifies the strength and direction of associations between 110 variables and provides interpretable results in terms of odds ratios. Both approaches carry 111 their strengths and limitations. However, we expect that true associations in the data (in this 112 case, sex-specific differential associations between iron biomarkers and PAD) should be 113 detected by both methods. Therefore, we initially used the ML approach to provide unbiased insight into our data and subsequently regression analyses to validate identified relationship. 114 115 An outline of the study is shown in Figure 1.

116

117 Methods

118 HEIST-DiC study

119 The Heidelberg Study on Diabetes and Complications (HEIST-DiC; https://clinicaltrials.gov; 120 NCT03022721) is a prospective, observational study designed to analyze the development 121 of complications in individuals with diabetes and prediabetes. We analyzed the data from 122 368 individuals enrolled in the HEIST-DiC study. The selection criteria for participants have been described previously¹⁸. We excluded participants with values of serum iron biomarkers 123 suggestive of hemochromatosis¹⁹. In addition, since ferritin not only indicates iron stores, but 124 125 also is an acute phase protein that responds to inflammation, we excluded participants with 126 ferritin> 400 ng/mL. For all participants, a detailed medical history was obtained. The ankle-127 brachial index (ABI) was measured using noninvasive blood pressure measurements of 128 arms and ankles (ABI System 1000; Boso d.o.o.). Blood samples were obtained in the 129 fasting state and all baseline parameters were analyzed under standardized conditions in the 130 central laboratory of the University Hospital of Heidelberg. Serum samples were stored at -131 80C until further analysis. We analyzed iron, ferritin, and TSAT as biomarkers of systemic 132 iron status, and assayed serum intercellular adhesion molecule-1 (ICAM1) and vascular-cell 133 adhesion molecule-1 (VCAM1) as markers of vascular dysfunction. We measured ICAM1 134 (#171B6009M) and VCAM1 (#171B6022M) in serum using multiplex magnetic bead-array-135 based technology on a BioPlex200 system (Bio-Rad) according to the manufacturer's 136 instructions. All participants provided written informed consent, and the ethics committees of the University of Heidelberg approved this study (Decision No. 204/2004, 400/2010, and S-137 138 383/2016) according to the Declaration of Helsinki.

139 **NHANES**

It is made available under a CC-BY-NC-ND 4.0 International license .

The National Health and Nutrition Examination Survey (NHANES) is designed to assess the health and nutritional status of adults and children in the United States. The survey includes both an interview (in which participants are asked questions about their health and lifestyle), and a physical examination component (in which various measurements and samples are collected). We obtained data from 15,969 participants over 40 years in 3 consecutive cycles of NHANES (1999-2004) for whom ABI was measured.

146

147 The demographic variables, age (in years) and body mass index (BMI) were used as is. Smoking and alcohol were categorized according to a previous study²⁰. We further 148 categorized diabetes based on self-reported history, current use of insulin or oral 149 150 hypoglycemic agents, fasting plasma glucose (FPG) ≥7.0 mM, or glycated hemoglobin 151 (HbA1c) ≥6.5%. Prediabetes was defined among those with an absent self-reported history 152 of diabetes by either FPG 5.6-6.9 mM or HbA1c 5.7-6.4%. We categorized hypertension 153 based on self-reported history or current use of anti-hypertensive agents or systolic blood 154 pressure >130 mmHg or diastolic blood pressure >80 mmHg. The presence of nonalcoholic fatty liver disease (NAFLD) was categorized by calculating the Fibrosis-4 Index score (FIB-4 155 score>3.25)²¹. As an index of insulin resistance, we calculated HOMA2-IR using C-peptide 156 values instead of insulin²². The use of antiplatelet and antihyperlipidemic medications was 157 categorized based on medication intake. 158

159

160 We applied the following exclusion criteria: not even one ABI measurement available, likely hemochromatosis¹⁹, anemia (hemoglobin <10g/L), elevated ferritin (>400 ng/mL), cancer, on 161 162 current hormonal medications or iron supplements, donated blood in the last 1 month, with 163 features of kidney disease (on dialysis or severe albuminuria), pregnant or breastfeeding in 164 the last year, high risk of liver fibrosis, concurrent inflammation [C-Reactive Protein (CRP) 165 >3 mg/dL] and with a feature of familial hyperlipidemia [LDL-Cholesterol (LDLc) >4.9 mM]. 166 This resulted in a final sample number of 5101 participants. We obtained data from the 167 following iron biomarkers: iron, ferritin, total iron binding capacity (TIBC), and TSAT. Assays 168 for the analytes in NHANES were performed under strict laboratory protocols (for more 169 details on data fields and procedure manuals, see Supplementary Table 1).

170

171 Categorization as PAD

172 In both cohorts, ABI values were measured on both the right and left limbs. We categorized

173 PAD when the ABI value on one of the sides was <0.9 or >1.4 as per recommendations²³.

174

175 Implementation of the ML framework

It is made available under a CC-BY-NC-ND 4.0 International license .

177 First, we preprocessed the HEIST-DiC and the NHANES dataset and removed all features 178 that contained more than 10% of missing values. Additionally, to made both cohorts 179 comparable by only considering the cases that did not have missing values for ferritin, 180 diabetes, CRP and high blood pressure in the NHANES cohort. For the HEIST-DiC dataset, 181 we have used the leave-one-out split strategy, and for each fold, we filled in the missing 182 values using the average of each column (SimpleImputer method, from Scikit-learn). Moreover, we used SMOTE (v0.12.0)²⁴ to oversample the minority class (PAD), to match 183 184 the majority class (No PAD). For the NHANES dataset, we used the 10-fold cross-validation 185 strategy, and for each fold, we filled the missing values and oversampled the minority class 186 using the same methods, and performed the so-called one-hot encoding, where we encoded 187 the categorical variables into numerical values. Next, for each dataset separately, we trained 188 the XGBoost classifier (v2.0.3)²⁵ and predicted the class of the instances on the test set, 189 from where we derived the balanced accuracy, the F1 Score, and quantified the feature 190 importance. Finally, we also implemented a version of the ML framework that allowed us to assess the variable importance using SHAP (SHapley Additive exPlanations, v0.44.0).²⁶ 191 192 Here, we performed the same steps for both HEIST and NHANES datasets, except that we 193 did not use any split strategy; instead, we filled the missing values, oversampled the minority 194 class and trained the classifier using the complete dataset. The ML pipeline is shown in 195 Figure 2A.

196

197 **Regression analysis**

198 For the regression analysis, we first tested the interaction effect of each of the iron 199 biomarkers with sex in both cohorts as iron metabolism is hallmarked by sex-specific 200 differences. Further, in the NHANES cohort, we conducted multivariable regression analyses 201 by flexibly modelling the probability of PAD's presence with one of the iron biomarkers (iron, 202 ferritin, or TSAT) by spline regression (degree of freedom=4). We chose variables from the 203 feature importance in ML analysis as covariates in the regression models on the NHANES 204 data: age, CRP, HDLc, triacylglycerols, HbA1c, ACR, BMI, ethnicity (non-Hispanic whites as 205 the reference), smoking (non-smokers as reference), the presence of diabetes, AST, ALT, 206 Hb, creatinine, antihyperlipidemic medications; the former seven variables as continuous 207 and the rest as categorical). All continuous variables were mean-centered for the analysis, 208 and variables were included in the models only when their missing data was <10%. In 209 addition, sample weights were included in the analyses of NHANES data.

210

All regression analyses were performed using R Statistical Software (v4.2.2²⁷). We used
Python (v3.10.12²⁸), and Scikit-learn (v1.4.0²⁹) for the implementation of the ML framework.
The reporting of the study is as per The Strengthening the Reporting of Observational

It is made available under a CC-BY-NC-ND 4.0 International license .

214 Studies in Epidemiology (STROBE) guidelines³⁰. We have also developed a data exploration

tool for readers to explore the datasets and interactively create their visualizations from the

216 paper (https://anandr.shinyapps.io/NHANES_HEISTDiC/) using Quarto³¹ and Shiny³².

217

218 Results

219 Demographics

220 The baseline characteristics of the HEIST-DiC participants are shown in Table 1. The overall 221 prevalence of PAD was 6.6% with a higher proportion among males (17/192) than females 222 (6/165). Among both sexes, the participants with PAD were older and diabetes and 223 hypertension was a common feature (Table 1). The sICAM1 and sVCAM1 levels were 224 significantly higher only among males with PAD (Table 1). Among the iron biomarkers, 225 ferritin was elevated among females, but not males, with PAD (Median 141, IQR 93-254, 226 p=0.035) while iron, transferrin, and TSAT were similar between HEIST-DIC participants with 227 and without PAD. (Table 1).

228

The analysis of NHANES builds on a previous report³³ by including data from the NHANES 229 230 2003-2004 cycle. The baseline characteristics of the NHANES participants included in the 231 study are shown in Table 2. Overall, the prevalence of PAD in the population was 6.25% 232 with a significantly higher prevalence among females (males: 4.96%, females: 7.9%; 233 p=0.001). Individuals with PAD showed differences in ethnicity, sex, presence of diabetes, 234 smoking, alcohol status, physical activity, and use of antihyperlipidemic and antiplatelet 235 medications (Table 2). Among the iron biomarkers, serum iron (Median 80, IQR 64-108 236 µg/dL; p<0.001) and transferrin saturation (Median 24, IQR 17-30; p=0.021) were reduced in males with PAD while females with PAD showed higher ferritin (Median 87, IQR 56-252 237 238 ng/mL; p < 0.001) and lower TIBC (Median 60, IQR 54-68; p < 0.001). Differences were also 239 observed in some laboratory parameters within both sexes with PAD (e.g. albumin, AST, 240 urea, creatinine, CRP, and ACR; Table 2).

241

242 Establishing a machine learning predictive framework for PAD

We next aimed to establish a predictive ML framework to anticipate the occurrence of PAD based on biomarkers. A so-called ML classifier is trained on a dataset containing instances with known outcomes (i.e., the presence or absence of PAD), and its relationship with input features. During the test phase, the trained classifier is used to predict PAD in participants unseen during the training phase, where we purposefully hid the true diagnostic. The result is then compared to the real diagnosis, and the quality of the framework is evaluated. Overall, this process enables the identification of subtle correlations between variables that

It is made available under a CC-BY-NC-ND 4.0 International license .

250 might be imperceptible to human analysis, but that can be used to anticipate PAD and 251 enhance our diagnostic capabilities.

252 Our framework received the available molecular and physiological biomarkers from 253 participants from two distinct cohorts, HEIST-DiC and NHANES as input. These cohorts 254 have unique characteristics that require the development of separate data preprocessing, 255 training, and testing regimens. First, the HEIST-DiC cohort comprised 357 instances (23 256 PAD and 334 No PAD cases) and had 35 numerical and categorical features. Here, for the 257 training and testing of the ML framework, we used a leave-one-out split methodology. This 258 approach involves using each instance as a test case once, while the remainder forms the 259 training set, thus maximizing the use of available data for training. In contrast, the NHANES 260 cohort was considerably larger, with 1188 instances (100 PAD and 1088 No PAD), and 28 261 features; hence, we used the 10-fold cross-validation strategy. This method divides the 262 dataset into ten parts, with each part successively used for testing while the other 9 parts are 263 used for training. Together, these strategies ensured robustness and reliability in our model's 264 predictive performance.

265

We found that the ML framework achieved a balanced accuracy of 95% for the HEIST cohort (Figure 2B-D) and 96% for the NHANES cohort (Figure 2E-G). Balanced accuracy is an important metric in the context of imbalanced datasets, where one of the classes has many times more instances than the other (in the case of HEIST-DiC, No PAD cases were 14 times more frequent, and in NHANES, 10 times). Thus, the balanced accuracy represents the average accuracy obtained on both classes (PAD and No PAD), which in turn ensures that our model is equally adept at identifying both conditions.

273

274 Moreover, the ML framework also achieved high F1 scores of 0.89 for HEIST-DiC and 0.93 275 for NHANES, pointing to a strong balance between precision (the proportion of true positive 276 results in all positive predictions), and recall (the proportion of true positive results in all 277 actual positives). Thus, the F1 score in combination with the balanced accuracy provides 278 realistic measures of a model's strength, particularly in datasets where one class might 279 significantly outnumber the other. In summary, the ML framework was effective in predicting 280 the occurrence of PAD across different cohorts, even in the face of data imbalance. Further, 281 sex and iron biomarkers were ranked among the top predictive markers for the presence of 282 PAD in the HEIST-DiC (ferritin, iron and transferrin) and the NHANES cohorts (ferritin, TIBC, 283 TSAT and iron; Supplementary Figure 2; Figure 3A-B).

284

285 Regression analyses

It is made available under a CC-BY-NC-ND 4.0 International license .

286 We next performed regression analyses on the HEIST-DiC data and tested the interaction 287 effect of each of the iron biomarkers with sex and found that ferritin showed a positive 288 association in females with PAD (Ferritin*Sex, OR 2.68, 95% CI 0.94-7.61, p=0.057) while, 289 iron (Iron*Sex, OR 1.17, 95% CI 0.44-2.96, p=0.7), transferrin (Transferrin*Sex, OR 1.28, 290 95% CI 0.48-3.17, p=0.6) and TSAT (TSAT*Sex, OR 1.1, 95% CI 0.35-3.2, p=0.9) were non-291 significant. Consistent with our observations in the HEIST-DiC cohort, we found that ferritin 292 also showed a significant interaction with sex in the NHANES cohort (Ferritin*Sex, OR 1.76, 293 95% CI 1.16-2.67, p=0.008). TIBC also had a significant negative interaction (TIBC*Sex, OR 294 0.61, 95% CI 0.4-0.92, p=0.018), while iron (Iron*Sex, OR 0.95, 95% CI 0.69-1.31, p=0.76) 295 and TSAT (TSAT*Sex, OR 1.15, 95% CI 0.84-1.58, p=0.37) were nonsignificant. 296

297 In the multivariable regression analyses of the NHANES data, we found that, ferritin or sex 298 alone do not show a statistically significant relationship with PAD. On the other hand, the 299 interaction between ferritin and sex reveals a significant positive association for two spline 300 components (Table 3). Specifically, ferritin showed positive and statistically significant effects 301 in females with two positions (48-97 ng/mL: OR 14.59, 95% Cl 1.6-135.93, p= 0.019; 98-169 ng/mL: OR 171.07, 95% CI 1.27-23404, p= 0.039); this suggests that the relationship 302 303 between PAD and ferritin is nonlinear and that within high ferritin ranges females show a 304 positive association with PAD. Other significant covariates include age, CRP, and smoking, all of which also positively impact the outcome. By contrast, no associations were significant 305 306 for iron and TSAT (Supplementary Table 2).

307

308 Discussion

Our study provides a comparison between ML and regression analyses to demonstrate the association between iron biomarkers in the context of PAD. Taken together, our findings from both analyses show that serum iron biomarkers are associated with PAD, with ferritin demonstrating a consistent association specifically in females with the two methodologies applied.

314

315 The positive association for higher serum ferritin among females with PAD strengthens previous observations on the NHANES 1999-2001 cohort³³. When this observation is 316 317 compared other related disease contexts to (e.g. carotid/coronary atherosclerosis/cardiovascular disease), ferritin's positive association agrees with some 318 studies^{11,15,16}, but not others^{34–36}. Our findings also agree with The Iron and Atherosclerosis 319 Study (FeAST; https://clinicaltrials.gov, NCT00032357), a major trial that investigated the 320 benefits of iron reduction on the clinical outcomes in a cohort of individuals with PAD³⁷. 321 322 While the initial analysis of the FeAST trial did not report a favorable outcome following

It is made available under a CC-BY-NC-ND 4.0 International license .

phlebotomy³⁷, the reanalysis of the results adjusting for the effects of age³⁸ and smoking³⁹ 323 324 have suggested that iron reduction (with ferritin and TSAT as endpoints) could be of 325 significant benefit for younger individuals and smokers. However, the FeAST trial did not contain sufficient participants to study sex-specific differences. Our study also advances 326 327 current knowledge. We extend the analyses by Menke et al³³, by including additional participants from the NHANES 2003-2004 cycle in the analysis. In contrast to the FeAST 328 329 trial³⁷, we have included participants with prediabetes, adjusted more stringently for 330 inflammation [excluded samples with features of inflammation (ferritin>400 ng/mL or CRP>3 331 mg/dL) and used CRP as a covariate] and increased statistical power to study sex-specific 332 differences.

333

334 If the high ferritin values observed in our study were solely interpreted as an indicator of 335 body iron stores, the data suggest that there is an increased risk of PAD at the upper end of, 336 what is clinically accepted as "physiological range". However, ferritin is also an acute-phase protein and inflammation influences most iron parameters. During inflammatory states, iron 337 338 export via ferroportin from macrophages and duodenal enterocytes is reduced by hepcidincontrolled⁴⁰ and transcriptional mechanisms^{41,42}. Consequently, macrophages become iron 339 340 loaded contributing to elevated circulating ferritin levels and hypoferremia (low iron levels in 341 the plasma)⁴³. Therefore, an alternative interpretation of our findings is that elevated ferritin may be an epiphenomenon secondary to inflammation. In addition, the presence of 342 343 microinflammation in tissues cannot be completely excluded from the available data.

344

To summarize, our study adds to the body of evidence suggesting sex-specific differences in PAD⁴⁴ and highlights a possible role of iron (directly or indirectly) in this relationship. We have partly controlled for hormonal influences by excluding NHANES participants who are currently pregnant, menstruating, lactating, or on hormonal contraceptives, but the hormone levels were not available to be included as covariates. It is further possible that additional sex-specific mechanisms are in play.

351 In both cohorts analyzed, we observed a similar prevalence of PAD (~6%) associated with 352 well-known risk factors (old age, diabetes, and hypertension). Markers related to metabolic 353 and vascular health, such as blood pressure, plasma glucose levels and CRP, were elevated 354 among PAD participants in both cohorts. Additionally, BMI was higher in PAD participants compared to non-PAD participants in HEIST-DiC, while NHANES shows more consistent 355 356 BMI values across groups, with a minor increase only in females with PAD. It is important to 357 note that the cohorts analyzed differed in that the HEIST-DiC cohort consisted of mainly 358 European individuals with diabetes and prediabetes from a hospital-based study, while

It is made available under a CC-BY-NC-ND 4.0 International license .

NHANES is a survey cohort, representative of the US population, and therefore contains amix of ethnicities.

361

362 The strength of our study lies in the analyses of these two independent cohorts by 363 orthogonal approaches, allowing for a generalization of the findings, an increased 364 robustness of the data, and a reduction of cohort-specific biases. The examination of 365 multiple iron biomarkers, including serum iron, ferritin, TSAT, and TIBC provides a 366 comprehensive analysis of the relationship between iron and clinically apparent PAD. To the 367 best of our knowledge, this is the first study to evaluate the relationship between iron 368 biomarkers and PAD in prediabetes and diabetes. Our approach also underscores the complementary nature of ML and regression analyses: while ML excels at predictive 369 370 accuracy and feature selection, regression analyses offer insights into interaction effects and 371 the nuanced relationship between predictors and outcomes. Therefore, integrating both 372 methodologies can leverage the strengths of each approach to provide a comprehensive 373 understanding of complex disease dynamics. Limitations include the cross-sectional nature 374 of the study which limits causal inferences and precludes the assessment of temporal 375 relationships. Further, we were unable to control for all possible confounding factors, such as 376 genetic predisposition, lifestyle, medications, or other comorbidities. The study described 377 here also did not investigate potential mechanisms underlying the observed associations.

378

379 Conclusion

Overall, our data show that elevated ferritin within the physiological range is associated with clinically apparent PAD in females but not males. Further studies are necessary to confirm whether the observed associations are indeed causal and to explore the potential mechanisms underlying this relationship. Our findings need to be considered explorative to encourage the investigation of potential biological pathways underlying the sex-specific differences in iron's influence on atherosclerosis.

386

387 Ethics statement

388

The ethics committees of the University of Heidelberg approved this study (Decision No. 204/2004, 400/2010, and S-383/2016) according to the Declaration of Helsinki. All participants entered the study according to the guidelines of the local ethics committees following written informed consent to participate.

393

394 Funding

It is made available under a CC-BY-NC-ND 4.0 International license .

396 The HEIST-DiC study was funded by the Deutsche Forschungsgemeinschaft (SFB1118). 397 MUM acknowledges funding from the Deutsche Forschungsgemeinschaft (DFG) (SFB1118; 398 GRK 2727; FerrOs - FOR5146; Ferroptosis SPP2306: Project No.461704553) and from the 399 Federal Ministry of Education and Research (NephrESA Nr 031L0191C; Translational Lung 400 Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL); Project 401 No. FKZ 82DZL004A1). 402 403 Author contributions 404 405 406 Anand Ruban Agarvas: Conceptualization, Methodology, Software, Formal analysis, 407 Investigation, Data curation, Writing- Original draft, Visualization 408 Stefan Kopf: Investigation, Resources, Writing - Review & Editing 409 Tiago J.S Lopes: Formal analysis, Investigation, Writing-Original draft, Visualization 410 Paul Thalmann: Validation, Writing - Review & Editing 411 José Manuel Fernández-Real: Methodology, Writing - Review & Editing, Supervision 412 Peter Nawroth: Project administration, Funding acquisition, Supervision, Writing - Review & 413 Editing 414 Martina U. Muckenthaler: Conceptualization, Methodology, Supervision, Writing - Review & 415 Editing, Project administration, Funding acquisition 416 417 **Conflict of interest** 418 419 None to declare 420 **Data and Code Availability Statement** 421 The 422 data from this study can be explored here: https://anandr.shinyapps.io/NHANES HEISTDiC/. The HEIST-DiC dataset analyzed in the 423 424 current study is available from the corresponding authors on reasonable request. The 425 NHANES dataset is publicly available. Codes used for data analysis and visualization are 426 accessible here (https://github.com/griffindoc/pad)

427

428 Funding

л	2	a
-	_	J

430 References

- 431
- 432 1. Aday AW, Matsushita K. Epidemiology of Peripheral Artery Disease and Polyvascular Disease.
- 433 *Circ Res.* 2021;128(12):1818-1832. doi:10.1161/CIRCRESAHA.121.318535

434 435 436 437	2.	Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UK, Williams LJ, Mensah GA, Criqui MH. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. <i>The Lancet</i> . 2013;382(9901):1329-1340. doi:10.1016/S0140-6736(13)61249-0
438 439 440	3.	Galy B, Conrad M, Muckenthaler M. Mechanisms controlling cellular and systemic iron homeostasis. <i>Nat Rev Mol Cell Biol</i> . Published online October 2, 2023. doi:10.1038/s41580-023-00648-1
441 442	4.	Sullivan JeromeL. IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK. <i>The Lancet.</i> 1981;317(8233):1293-1294. doi:10.1016/S0140-6736(81)92463-6
443 444 445	5.	Bai T, Li M, Liu Y, Qiao Z, Wang Z. Inhibition of ferroptosis alleviates atherosclerosis through attenuating lipid peroxidation and endothelial dysfunction in mouse aortic endothelial cell. <i>Free Radic Biol Med</i> . 2020;160:92-102. doi:10.1016/j.freeradbiomed.2020.07.026
446 447 448 449	6.	Moreau KL, Stauffer BL, Kohrt WM, Seals DR. Essential Role of Estrogen for Improvements in Vascular Endothelial Function With Endurance Exercise in Postmenopausal Women. <i>The</i> <i>Journal of Clinical Endocrinology & Metabolism</i> . 2013;98(11):4507-4515. doi:10.1210/jc.2013- 2183
450 451 452	7.	Taddei S, Virdis A, Ghiadoni L, Mattei P, Sudano I, Bernini G, Pinto S, Salvetti A. Menopause Is Associated With Endothelial Dysfunction in Women. <i>Hypertension</i> . 1996;28(4):576-582. doi:10.1161/01.HYP.28.4.576
453 454 455	8.	Yang Q, Jian J, Katz S, Abramson SB, Huang X. 17β-Estradiol Inhibits Iron Hormone Hepcidin Through an Estrogen Responsive Element Half-Site. <i>Endocrinology</i> . 2012;153(7):3170-3178. doi:10.1210/en.2011-2045
456 457 458 459	9.	Li X, Rhee DK, Malhotra R, Mayeur C, Hurst LA, Ager E, Shelton G, Kramer Y, McCulloh D, Keefe D, Bloch KD, Bloch DB, Peterson RT. Progesterone receptor membrane component-1 regulates hepcidin biosynthesis. <i>Journal of Clinical Investigation</i> . 2015;126(1):389-401. doi:10.1172/JCI83831
460 461 462 463	10.	Vinchi F, Porto G, Simmelbauer A, Altamura S, Passos ST, Garbowski M, Silva AMN, Spaich S, Seide SE, Sparla R, Hentze MW, Muckenthaler MU. Atherosclerosis is aggravated by iron overload and ameliorated by dietary and pharmacological iron restriction. <i>Eur Heart J</i> . Published online March 20, 2019. doi:10.1093/eurheartj/ehz112
464 465 466 467	11.	Wolff B, Völzke H, Lüdemann J, Robinson D, Vogelgesang D, Staudt A, Kessler C, Dahm JB, John U, Felix SB. Association between high serum ferritin levels and carotid atherosclerosis in the study of health in Pomerania (SHIP). <i>Stroke</i> . 2004;35(2):453-457. doi:10.1161/01.STR.0000114875.31599.1C
468 469 470	12.	Sung KC, Kang SM, Cho EJ, Park JB, Wild SH, Byrne CD. Ferritin Is Independently Associated With the Presence of Coronary Artery Calcium in 12 033 Men. <i>ATVB</i> . 2012;32(10):2525-2530. doi:10.1161/ATVBAHA.112.253088
471 472 473	13.	Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. <i>Circulation</i> . 1997;96(10):3300-3307. doi:10.1161/01.cir.96.10.3300

14.	Das De S, Krishna S, Jethwa A. Iron status and its association with coronary heart disease: systematic review and meta-analysis of prospective studies. <i>Atherosclerosis</i> . 2015;238(2):296- 303. doi:10.1016/j.atherosclerosis.2014.12.018
15.	Guo S, Mao X, Li X, Ouyang H. Association between iron status and incident coronary artery disease: a population based-cohort study. <i>Sci Rep</i> . 2022;12(1):17490. doi:10.1038/s41598-022-22275-0
16.	Klip IjT, Voors AA, Swinkels DW, Bakker SJL, Kootstra-Ros JE, Lam CS, Van Der Harst P, Van Veldhuisen DJ, Van Der Meer P. Serum ferritin and risk for new-onset heart failure and cardiovascular events in the community: Serum ferritin and risk for new-onset HF and CV events. <i>Eur J Heart Fail</i> . 2017;19(3):348-356. doi:10.1002/ejhf.622
17.	Gill D, Brewer CF, Monori G, Trégouët DA, Franceschini N, Giambartolomei C, INVENT Consortium, Tzoulaki I, Dehghan A. Effects of Genetically Determined Iron Status on Risk of Venous Thromboembolism and Carotid Atherosclerotic Disease: A Mendelian Randomization Study. J Am Heart Assoc. 2019;8(15):e012994. doi:10.1161/JAHA.119.012994
18.	Altamura S, Kopf S, Schmidt J, Müdder K, da Silva AR, Nawroth P, Muckenthaler MU. Uncoupled iron homeostasis in type 2 diabetes mellitus. <i>J Mol Med</i> . 2017;95(12):1387-1398. doi:10.1007/s00109-017-1596-3
19.	Zoller H, Schaefer B, Vanclooster A, Griffiths B, Bardou-Jacquet E, Corradini E, Porto G, Ryan J, Cornberg M. EASL Clinical Practice Guidelines on haemochromatosis. <i>Journal of Hepatology</i> . 2022;77(2):479-502. doi:10.1016/j.jhep.2022.03.033
20.	Qiu Z, Chen X, Geng T, Wan Z, Lu Q, Li L, Zhu K, Zhang X, Liu Y, Lin X, Chen L, Shan Z, Liu L, Pan A, Liu G. Associations of Serum Carotenoids With Risk of Cardiovascular Mortality Among Individuals With Type 2 Diabetes: Results From NHANES. <i>Diabetes Care</i> . 2022;45(6):1453-1461. doi:10.2337/dc21-2371
21.	Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, Hall R, Harrower U, Hudson M, Langford A, Mackie A, Mitchell-Thain R, Sennett K, Sheron NC, Verne J, Walmsley M, Yeoman A. Guidelines on the management of abnormal liver blood tests. <i>Gut</i> . 2018;67(1):6- 19. doi:10.1136/gutjnl-2017-314924
22.	Ahlqvist E, Prasad RB, Groop L. Subtypes of Type 2 Diabetes Determined From Clinical Parameters. <i>Diabetes</i> . 2020;69(10):2086-2093. doi:10.2337/dbi20-0001
23.	Aboyans V, Ricco JB, Bartelink MLEL, Björck M, Brodmann M, Cohnert T, Collet JP, Czerny M, De Carlo M, Debus S, Espinola-Klein C, Kahan T, Kownator S, Mazzolai L, Naylor AR, Roffi M, Röther J, Sprynger M, Tendera M, Tepe G, Venermo M, Vlachopoulos C, Desormais I, ESC Scientific Document Group, Widimsky P, Kolh P, Agewall S, Bueno H, Coca A, De Borst GJ, Delgado V, Dick F, Erol C, Ferrini M, Kakkos S, Katus HA, Knuuti J, Lindholt J, Mattle H, Pieniazek P, Piepoli MF, Scheinert D, Sievert H, Simpson I, Sulzenko J, Tamargo J, Tokgozoglu L, Torbicki A, Tsakountakis N, Tuñón J, De Ceniga MV, Windecker S, Zamorano JL, Windecker S, Aboyans V, Agewall S, Barbato E, Bueno H, Coca A, Collet JP, Coman IM, Dean V, Delgado V, Fitzsimons D, Gaemperli O, Hindricks G, Iung B, Juni P, Katus HA, Knuuti J, Lancellotti P, Leclercq C, McDonagh T, Piepoli MF, Ponikowski P, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Zamorano JL, Zelveian PH, Haumer M, Isachkin D, De Backer T, Dilic M, Petrov I, Kirhmajer MV, Karetova D, Prescott E, Soliman H, Paapstel A, Makinen K, Tosev S, Messas E, Pagava Z, Müller OJ, Naka KK, Járai Z, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in
	 14. 15. 16. 17. 18. 19. 20. 21. 22. 23.

517 518		collaboration with the European Society for Vascular Surgery (ESVS). <i>European Heart Journal</i> . 2018;39(9):763-816. doi:10.1093/eurheartj/ehx095
519 520	24.	Chawla NV, Bowyer KW, Hall LO, Kegelmeyer WP. SMOTE: Synthetic Minority Over-sampling Technique. <i>jair</i> . 2002;16:321-357. doi:10.1613/jair.953
521 522 523	25.	Chen T, Guestrin C. XGBoost: A Scalable Tree Boosting System. In: <i>Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining</i> . ACM; 2016:785-794. doi:10.1145/2939672.2939785
524 525	26.	Lundberg S, Lee SI. A Unified Approach to Interpreting Model Predictions. Published online 2017. doi:10.48550/ARXIV.1705.07874
526 527	27.	R Core Team. R: A Language and Environment for Statistical Computing. Published online 2022. https://www.R-project.org/
528 529	28.	Rossum G van, Drake FL. <i>The Python Language Reference</i> . Release 3.0.1 [Repr.]. Python Software Foundation; 2010.
530 531 532 533	29.	Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, Blondel M, Prettenhofer P, Weiss R, Dubourg V, Vanderplas J, Passos A, Cournapeau D, Brucher M, Perrot M, Duchesnay É. Scikit-learn: Machine Learning in Python. <i>Journal of Machine Learning Research</i> . 2011;12(85):2825-2830.
534 535 536 537	30.	von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. <i>Lancet</i> . 2007;370(9596):1453-1457. doi:10.1016/S0140-6736(07)61602-X
538 539	31.	Allaire J. quarto: R Interface to "Quarto" Markdown Publishing System R package version 1.2. Published online 2022. https://CRAN.R-project.org/package=quarto
540 541 542	32.	Chang W, Cheng J, Allaire J, Sievert C, Schloerke B, Xie Y, Allen J, McPherson J, Dipert A, Borges B. Shiny: Web Application Framework for R R package version 1.7.4.1. Published online 2023. https://CRAN.R-project.org/package=shiny
543 544 545	33.	Menke A, Fernández-Real JM, Muntner P, Guallar E. The association of biomarkers of iron status with peripheral arterial disease in US adults. <i>BMC Cardiovasc Disord</i> . 2009;9(1):34. doi:10.1186/1471-2261-9-34
546 547 548 549	34.	Zhou J, Zhao R, Wang D, Gao Q, Zhao D, Ouyang B, Hao L, Peng X. Sex-Specific Association Between Iron Status and the Predicted 10-Year Risk for Atherosclerotic Cardiovascular Disease in Hypertensive Patients. <i>Biol Trace Elem Res</i> . 2022;200(11):4594-4607. doi:10.1007/s12011- 021-03060-y
550 551 552 553	35.	Ellervik C, Marott JL, Tybjærg-Hansen A, Schnohr P, Nordestgaard BG. Total and cause-specific mortality by moderately and markedly increased ferritin concentrations: general population study and metaanalysis. <i>Clin Chem</i> . 2014;60(11):1419-1428. doi:10.1373/clinchem.2014.229013
554 555	36.	Kadoglou NPE, Biddulph JP, Rafnsson SB, Trivella M, Nihoyannopoulos P, Demakakos P. The association of ferritin with cardiovascular and all-cause mortality in community-dwellers: The

EEC E	nalich longiti	udinal study of	facoing Dia	C 0 no 2017.	2/61-2001
330 E	IISII SII IOIISIU	Jullial Sluuv O	i agenig, <i>PLU</i>	3 Une. 2017	LZ(0), EUL/0334.

557 doi:10.1371/journal.pone.0178994

37. Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, Ozaki CK,
Lavori PW. Reduction of Iron Stores and Cardiovascular Outcomes in Patients With Peripheral
Arterial Disease: A Randomized Controlled Trial. *JAMA*. 2007;297(6):603.

561 doi:10.1001/jama.297.6.603

38. Zacharski LR, Shamayeva G, Chow BK. Effect of controlled reduction of body iron stores on
clinical outcomes in peripheral arterial disease. *American Heart Journal*. 2011;162(5):949957.e1. doi:10.1016/j.ahj.2011.08.013

56539.DePalma RG, Zacharski LR, Chow BK, Shamayeva G, Hayes VW. Reduction of iron stores and566clinical outcomes in peripheral arterial disease: outcome comparisons in smokers and non-567smokers. Vascular. 2013;21(4):233-241. doi:10.1177/1708538113478776

- 568 40. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J.
 569 Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization.
 570 Science. 2004;306(5704):2090-2093. doi:10.1126/science.1104742
- Guida C, Altamura S, Klein FA, Galy B, Boutros M, Ulmer AJ, Hentze MW, Muckenthaler MU. A
 novel inflammatory pathway mediating rapid hepcidin-independent hypoferremia. *Blood*.
 2015;125(14):2265-2275. doi:10.1182/blood-2014-08-595256

42. Marques O, Weiss G, Muckenthaler MU. The role of iron in chronic inflammatory diseases:
575 from mechanisms to treatment options in anemia of inflammation. *Blood*. 2022;140(19):2011576 2023. doi:10.1182/blood.2021013472

577 43. Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang D liang, Crooks DR, Sougrat R,
578 Morgenstern A, Galy B, Hentze MW, Lazaro FJ, Rouault TA, Meyron-Holtz EG. Serum ferritin is
579 derived primarily from macrophages through a nonclassical secretory pathway. *Blood*.
580 2010;116(9):1574-1584. doi:10.1182/blood-2009-11-253815

44. Pabon M, Cheng S, Altin SE, Sethi SS, Nelson MD, Moreau KL, Hamburg N, Hess CN. Sex
Differences in Peripheral Artery Disease. *Circ Res.* 2022;130(4):496-511.
doi:10.1161/CIRCRESAHA.121.320702

It is made available under a CC-BY-NC-ND 4.0 International license .

585

586 Legends

587 **Table 1. Demographics of HEIST-DiC participants**

The demographics of the HEIST-DiC participants classified by sex and the presence of PAD are shown in Table 1. For continuous variables, the summary data are shown as Mean±Standard Deviation and for categorical variables as N (%). P-values as calculated by the Wilcoxon rank sum test or Pearson's Chi-squared test^C and significant P-values are boldfaced.

BMI: Body Mass Index, HDL: High-Density Lipoprotein, LDL: Low-Density Lipoprotein,
HbA1c: Glycated hemoglobin, ICAM1: Intercellular Adhesion Molecule 1, VCAM1: Vascular
Cell Adhesion Molecule 1, hsCRP: High sensitivity C-reactive protein, IL6: Interleukin 6,
hsTNT: High sensitivity Troponin T, proBNP: N-Terminal B-type Natriuretic Peptide, eGFR:
Estimated Glomerular Filtration Rate, TSAT: Transferrin Saturation

598

599 Table 2. Demographics of NHANES 1999-2004 participants

The demographics of the NHANES 1999-2004 participants classified by sex and the presence of PAD are shown in Table 2. The ¹N of participants shown are unweighted numbers. For continuous variables, the summary data are shown as Median (Interquartile Range), and for categorical variables as N (%)- survey weights were included in calculating the summary data. P-values as calculated by the Wilcoxon rank-sum test for complex survey samples or chi-squared test with Rao & Scott's second-order correction^C and significant Pvalues are boldfaced.

607 BMI: Body Mass Index, HDL: High-Density Lipoprotein, LDL: Low-Density Lipoprotein, 608 HbA1c: Glycated hemoglobin, CRP: High sensitivity C-reactive protein, eGFR: Estimated 609 Glomerular Filtration Rate, TSAT: Transferrin Saturation, TIBC: Total Iron Binding Capacity, 610 AST: Aspartate Aminotransferase, ALT: Alanine Aminotransferase, FIB4 Score: Fibrosis-4 611 index Score

612

613 Table 3. Multivariable regression analysis of ferritin and PAD in the NHANES Cohort

614 We conducted multivariable regression analyses by flexibly modelling the probability of 615 PAD's presence with ferritin by spline regression (degree of freedom=4). The following 616 variables were included a covariates: age, CRP, HDLc, triacylglycerols, HbA1c, ACR, BMI, 617 ethnicity (non-Hispanic whites as the reference), smoking (non-smokers as reference), the 618 presence of diabetes, AST, ALT, Hb, creatinine, antihyperlipidemic medications; the former 619 seven variables as continuous and the rest as categorical). All continuous variables were 620 mean-centered for the analysis. In addition, sample weights were included in the analyses 621 BMI: Body Mass Index, HDL: High-Density Lipoprotein, CRP: High sensitivity C-reactive 622 protein, AST: Aspartate Aminotransferase, ALT: Alanine Aminotransferase; ACR: Albumin-623 creatinine ratio, OR: Odds Ratio, 95% CI: 95% Confidence Interval, SE: Standard Error 624

625

626 Figure 1. Outline of the study and analysis approach

627

Figure 2. Setup and results of the machine learning approach

(A) The datasets were divided using either cross-fold validation (NHANES), or the leave-one-out strategy (HEIST-DIC). Next, the categorical variables were transformed into binary values (the so-called 'hot-encode'), we filled missing values and oversampled the minority classes (see Methods). After training the classifier, the instances of the test set had their classes predicted, and we evaluated the results using classical ML metrics. (B-D) The ROC and precision-recall curves of the HEIST-DIC cohort data, and its confusion matrix. (E-G)
The ROC and precision-recall curves of the NHANES cohort data, and its confusion matrix.

636

637 Figure 3. Feature importance of machine learning classification

(A-B) We used the SHAP method to quantify the importance of the features that werecontributing the most to the prediction of PAD occurrence. Here, higher values indicate a

It is made available under a CC-BY-NC-ND 4.0 International license .

higher contribution of a given feature. In both panels, iron-related markers are color-coded,and appear among the top features in terms of relevance to the prediction of PAD.

642 643

644 Supplementary files

- 645
- 646

647 Supplementary Table 1. Data fields and variables from NHANES 1999-2004.

The table shows the variables and the corresponding codes used for accessing data from the NHANES. The hyperlinks to the procedure manuals and datafiles are also provided in the table.

651

Supplementary Table 2. Multivariable regression analysis of iron biomarkers and PAD in the NHANES Cohort

We conducted multivariable regression analyses by flexibly modelling the probability of 654 655 PAD's presence with iron biomarkers (iron or TSAT) by spline regression (degree of freedom=4). The following variables were included aas covariates: age, CRP, HDLc, 656 657 triacylglycerols, HbA1c, ACR, BMI, ethnicity (non-Hispanic whites as the reference), smoking 658 (non-smokers as reference), the presence of diabetes, AST, ALT, Hb, creatinine, 659 antihyperlipidemic medications; the former seven variables as continuous and the rest as 660 categorical). All continuous variables were mean-centered for the analysis. In addition, 661 sample weights were included in the analyses

662 BMI: Body Mass Index, HDL: High-Density Lipoprotein, CRP: High sensitivity C-reactive 663 protein, AST: Aspartate Aminotransferase, ALT: Alanine Aminotransferase; ACR: Albumin-664 creatinine ratio, OR: Odds Ratio, 95% CI: 95% Confidence Interval, SE: Standard Error 665

666

667 Supplementary Figure 1. Feature importance of xGBoost classification

(A-B) We used the XGBoost classifier and its output to quantify the importance of the
features to the prediction of PAD occurrence. In both panels, higher values indicate a higher
contribution of a given feature, and iron-related markers are color coded, and appear among
the top features in terms of relevance to the prediction of this condition.

- 672
- 673
- 674

		Male	S			Femal	es	
Variable	Overall $N = 192^1$	No PAD N = 175 ¹	PAD N = 17 ¹	p- value ²	Overall $N = 165^1$	No PAD N = 159 ¹	PAD N = 6 ¹	p- value ²
Age (years)	63 (54, 69)	62 (54, 69)	70 (66, 76)	<0.001	60 (53, 67)	59 (52, 67)	69 (62, 73)	0.025
BMI (kg/sq.m)	29.0 (25.9, 32.9)	29.0 (25.9, 33.0)	29.7 (26.2, 32.9)	0.6	29.4 (24.9, 33.0)	29.3 (24.8, 33.0)	32.8 (30.5, 40.4)	0.036
Hypertension								
No	70 (36%)	67 (38%)	3 (18%)	0.2	82 (50%)	82 (52%)	0 (0%)	0.039
Yes	122 (64%)	108 (62%)	14 (82%)	-	83 (50%)	77 (48%)	6 (100%)	
Diabetes								
No diabetes	37 (19%)	37 (21%)	0 (0%)	0.11	67 (41%)	66 (42%)	1 (17%)	0.2
Prediabetes	19 (9.9%)	17 (9.7%)	2 (12%)		18 (11%)	18 (11%)	0 (0%)	
Diabetes	136 (71%)	121 (69%)	15 (88%)	2	80 (48%)	75 (47%)	5 (83%)	
Dietary manageme	ent							
No	170 (89%)	156 (89%)	14 (82%)	0.7	155 (94%)	150 (94%)	5 (83%)	0.8
Yes	22 (11%)	19 (11%)	3 (18%)		10 (6.1%)	9 (5.7%)	1 (17%)	
Oral antidiabetic n	nedications use)		1	I			
No	125 (65%)	115 (66%)	10 (59%)	0.8	122 (74%)	118 (74%)	4 (67%)	>0.9
Yes	67 (35%)	60 (34%)	7 (41%)		43 (26%)	41 (26%)	2 (33%)	
			Stati	ns use		·		

129 (67%)	118 (67%)	11 (65%)	>0.9	136 (82%)	132 (83%)	4 (67%)	0.6			
63 (33%)	57 (33%)	6 (35%)		29 (18%)	27 (17%)	2 (33%)				
Insulin use										
157 (82%)	145 (83%)	12 (71%)	0.4	141 (85%)	137 (86%)	4 (67%)	0.5			
35 (18%)	30 (17%)	5 (29%)		24 (15%)	22 (14%)	2 (33%)				
127 (103, 161)	125 (102, 154)	167 (123, 204)	0.002	106 (92, 145)	105 (92, 139)	152 (139, 174)	0.067			
6.40 (5.70, 7.50)	6.40 (5.60, 7.40)	7.50 (6.30, 7.90)	0.014	5.80 (5.40, 6.80)	5.80 (5.40, 6.80)	7.10 (6.60, 8.20)	0.056			
cular function										
1.10 (1.03, 1.16)	1.11 (1.06, 1.16)	0.86 (0.76, 0.88)	<0.001	1.08 (1.02, 1.15)	1.09 (1.03, 1.15)	0.82 (0.76, 0.86)	<0.001			
1.10 (1.05, 1.16)	1.11 (1.06, 1.17)	0.92 (0.88, 0.95)	<0.001	1.09 (1.04, 1.15)	1.09 (1.05, 1.15)	0.97 (0.86, 0.98)	<0.001			
0.60 (0.54, 0.70)	0.60 (0.54, 0.70)	0.70 (0.59, 0.85)	0.025	0.60 (0.50, 0.66)	0.58 (0.50, 0.65)	0.83 (0.70, 0.98)	0.002			
8.70 (7.70, 9.80)	8.70 (7.60, 9.70)	9.75 (9.55, 11.50)	0.004	8.10 (7.10, 9.70)	8.10 (7.10, 9.60)	11.35 (11.00, 12.60)	0.002			
294 (212, 366)	289 (206, 357)	380 (303, 419)	0.008	305 (225, 363)	305 (229, 367)	225 (218, 363)	0.6			
847 (692, 1,052)	827 (682, 1,033)	1,104 (878,	0.017	804 (697, 961)	803 (697, 962)	856 (467, 905)	0.8			
	129 (67%) 63 (33%) 157 (82%) 35 (18%) 127 (103, 161) 6.40 (5.70, 7.50) cular function 1.10 (1.03, 1.16) 1.10 (1.05, 1.16) 0.60 (0.54, 0.70) 8.70 (7.70, 9.80) 294 (212, 366) 847 (692, 1,052)	129 (67%) $118 (67%)$ $63 (33%)$ $57 (33%)$ $157 (82%)$ $145 (83%)$ $35 (18%)$ $30 (17%)$ $127 (103, 125 (102, 154)$ $6.40 (5.70, 7.50)$ $6.40 (5.60, 7.40)$ $cular function$ $1.10 (1.03, 1.11 (1.06, 1.16)$ $1.10 (1.05, 1.11 (1.06, 1.16)$ $1.10 (1.05, 1.11 (1.06, 1.17)$ $0.60 (0.54, 0.60 (0.54, 0.70)$ $0.60 (0.54, 0.70)$ $8.70 (7.70, 9.80)$ $8.70 (7.60, 9.70)$ $294 (212, 366)$ $847 (692, 1.033)$ $847 (692, 1.033)$	129 (67%) $118 (67%)$ $11 (65%)$ $63 (33%)$ $57 (33%)$ $6 (35%)$ $157 (82%)$ $145 (83%)$ $12 (71%)$ $35 (18%)$ $30 (17%)$ $5 (29%)$ $127 (103, 125 (102, 167 (123, 204))$ $167 (123, 204)$ $6.40 (5.70, 7.50)$ $6.40 (5.60, 7.50 (6.30, 7.90)$ $7.50)$ $6.40 (5.60, 7.50 (6.30, 7.90)$ $1.10 (1.03, 1.11 (1.06, 1.16)$ $0.86 (0.76, 0.88)$ $1.10 (1.05, 1.11 (1.06, 1.16)$ $0.92 (0.88, 0.95)$ $1.10 (1.05, 1.11 (1.06, 0.92) (0.88, 0.95)$ $0.70) (0.59, 0.70)$ $0.60 (0.54, 0.60 (0.54, 0.70)$ $0.70 (0.59, 0.70) (0.59, 0.70)$ $8.70 (7.70, 9.80)$ $8.70 (7.60, 9.75 (9.55, 11.50)$ $294 (212, 289 (206, 380 (303, 419))$ $380 (303, 419)$ $847 (692, 1.052)$ $827 (682, 1.104 (878, 10.95))$	$\begin{array}{c c c c c c c c } 129(67\%) & 118(67\%) & 11(65\%) & >0.9 \\ \hline & 63(33\%) & 57(33\%) & 6(35\%) & \\ \hline & 6(35\%) & \\ \hline & 6(35\%) & \\ \hline & 157(82\%) & 145(83\%) & 12(71\%) & \\ & 35(18\%) & 30(17\%) & 5(29\%) & \\ \hline & 127(103, & 125(102, & 167(123, & 0.002 & \\ 127(103, & 125(102, & 167(123, & 204) & \\ \hline & 127(103, & 125(102, & 167(123, & 204) & \\ \hline & 127(103, & 125(102, & 167(123, & 204) & \\ \hline & 6.40(5.70, & 6.40(5.60, & 7.50(6.30, & 0.001 & \\ \hline & 6.40(5.70, & 6.40(5.60, & 7.50(6.30, & 0.014 & \\ \hline & 1.10(1.03, & 1.11(1.06, & 0.86(0.76, & 0.88) & \\ \hline & 1.10(1.05, & 1.11(1.06, & 0.92(0.88, & <0.001 & \\ \hline & 1.10(1.05, & 1.11(1.06, & 0.92(0.88, & <0.001 & \\ \hline & 1.10(1.05, & 1.11(1.06, & 0.92(0.88, & <0.001 & \\ \hline & 1.16 & 0.70 & 0.59, & 0.025 & \\ \hline & 8.70(7.70, & 8.70(7.60, & 9.75(9.55, & \\ 9.80) & 9.70) & 11.50) & \\ \hline & 8.70(7.70, & 8.70(7.60, & 380(303, & 0.008 & \\ \hline & 847(692, & 357) & 327(682, & 1,104 & \\ 1,052) & 827(682, & 1,104 & (878, & \\ \hline & 1.104(878, & & \\ \hline & 1.104(87$	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $			

			1,189)					
Other laboratory p	arameters							
Triacylglycerols (mg/dL)	128 (90, 199)	125 (87, 191)	177 (148, 247)	0.011	119 (82, 166)	118 (80, 163)	177 (128, 207)	0.092
Cholesterol (mg/dL)	184 (157, 221)	184 (156, 221)	183 (159, 216)	0.8	204 (173, 231)	204 (173, 231)	184 (159, 240)	0.5
HDL (mg/dL)	46 (39, 55)	47 (39, 55)	40 (38, 47)	0.067	57 (47, 71)	58 (47, 71)	50 (37, 57)	0.3
LDL (mg/dL)	107 (82, 134)	107 (82, 135)	107 (83, 132)	0.9	116 (89, 139)	116 (90, 139)	81 (78, 116)	0.088
Hemoglobin (g/dL)	14.90 (14.10, 15.50)	14.90 (14.10, 15.50)	14.30 (13.20, 15.10)	0.14	13.60 (13.00, 14.20)	13.60 (13.00, 14.20)	13.25 (12.80, 14.00)	0.5
Mean Corpuscular Volume (fL)	89.0 (86.0, 92.0)	89.0 (86.0, 92.0)	90.0 (87.0, 92.0)	0.2	88.0 (85.0, 91.0)	88.0 (85.0, 91.0)	87.5 (84.0, 91.0)	0.7
hsCRP (mg/L)	1.09 (0.52, 2.54)	1.05 (0.51, 2.35)	1.32 (0.79, 4.36)	0.3	2.1 (0.7, 4.7)	1.9 (0.7, 4.6)	5.0 (2.9, 15.1)	0.083
IL6 (pg/mL)	2.45 (2.00, 3.70)	2.35 (2.00, 3.60)	3.20 (2.40, 4.20)	0.010	2.55 (2.00, 4.15)	2.50 (2.00, 4.10)	3.80 (2.50, 6.90)	0.3
hsTNT (ng/L)	9.0 (7.0, 13.0)	9.0 (7.0, 12.0)	11.0 (9.0, 20.0)	0.033	6.0 (4.0, 8.0)	6.0 (4.0, 8.0)	9.0 (8.0, 9.0)	0.2
proBNP (pg/mL)	60 (31, 129)	59 (29, 118)	113 (35, 251)	0.052	71 (39, 130)	69 (37, 121)	175 (135, 236)	0.008
eGFR (ml/min/1.73m ²)	91 (80, 100)	92 (82, 101)	76 (62, 91)	0.002	93 (81, 101)	93 (82, 101)	64 (50, 86)	0.016

Urinary Albumin Creatinine Ratio (mg/g)	8 (4, 23)	8 (4, 18)	25 (11, 139)	0.001	7 (4, 14)	7 (4, 13)	26 (14, 111)	0.012
Iron-related param	eters							
Iron (μM)	95 (75, 119)	96 (75, 120)	85 (76, 108)	0.7	90 (71, 118)	90 (70, 118)	95 (79, 126)	0.6
Ferritin (ng/mL)	155 (81, 259)	153 (78, 250)	192 (126, 306)	0.10	79 (44, 136)	77 (42, 131)	141 (90, 278)	0.031
Transferrin (g/L)	2.38 (2.18, 2.61)	2.38 (2.18, 2.61)	2.24 (2.15, 2.73)	0.6	2.42 (2.24, 2.69)	2.42 (2.24, 2.67)	2.56 (2.16, 2.88)	0.6
TSAT (%)	25 (20, 32)	26 (20, 33)	23 (21, 27)	0.2	24 (18, 31)	25 (18, 31)	22 (19, 24)	0.5

¹Median (Q1, Q3); n (%)

Table 1. Demographics of HEIST-DiC participants

The demographics of the HEIST-DiC participants classified by sex and the presence of PAD are shown in Table 1. For continuous variables, the summary data are shown as Mediann (Q1, Q3) and for categorical variables as N (%). P-values as calculated by the Wilcoxon rank sum test or Pearson's Chi-squared test^C and significant P-values are boldfaced.

BMI: Body Mass Index, HDL: High-Density Lipoprotein, LDL: Low-Density Lipoprotein, HbA1c: Glycated hemoglobin, ICAM1: Intercellular Adhesion Molecule 1, VCAM1: Vascular Cell Adhesion Molecule 1, hsCRP: High sensitivity C-reactive protein, IL6: Interleukin 6, hsTNT: High sensitivity Troponin T, proBNP: N-Terminal B-type Natriuretic Peptide, eGFR: Estimated Glomerular Filtration Rate, TSAT: Transferrin Saturation

		Male	S			Femal	es	
Characteristic	Overall N = 2792 ¹	No PAD, N = 2573 ¹	1, N = 219 ¹	p- value ²	Overall N =2309 ¹	0, N = 2082 ¹	1, N = 227 ¹	p- value ²
Ethnicity					·			
Non-Hispanic White	1459 (78%)	1330 (78%)	129 (83%)	0.003	1089 (73%)	971 (72%)	118 (76%)	<0.001
Non-Hispanic Black	497 (9.0%)	454 (8.9%)	43 (11%)		475 (11%)	418 (11%)	57 (16%)	
Mexican- American	662 (5.6%)	619 (5.6%)	43 (5.2%)		546 (5.0%)	504 (5.1%)	42 (4.2%)	
Others	174 (7.6%)	170 (7.9%)	4 (1.2%)		199 (11%)	189 (12%)	10 (4.0%)	
Age (years)	52 (45, 61)	51 (45, 60)	68 (60, 76)	<0.001	52 (45, 65)	51 (45, 64)	70 (54, 81)	<0.001
BMI (kg/sq.m)	27.9 (25.1, 31.0)	27.9 (25.1, 30.9)	27.8 (25.0, 32.2)	>0.9	27 (24, 32)	27 (24, 32)	29 (25, 34)	0.034
Diabetes (coded)								
No diabetes	1796 (75%)	1698 (76%)	98 (49%)	<0.001	1461 (73%)	1358 (75%)	103 (51%)	<0.001
Prediabetes	444 (13%)	387 (12%)	57 (27%)		418 (16%)	357 (15%)	61 (25%)	
Diabetes	450 (12%)	395 (12%)	55 (24%)		349 (11%)	296 (10%)	53 (23%)	
Hypertension (cod	led)							
No	252 (14%)	233 (14%)	19 (13%)	0.9	209 (15%)	188 (15%)	21 (14%)	0.9
Yes	1557	1404	153 (87%)		1296	1129	167 (86%)	

	(86%)	(86%)			(85%)	(85%)				
Smoking (coded)	Smoking (coded)									
Nonsmoker	974 (36%)	931 (37%)	43 (18%)	<0.001	1397 (58%)	1277 (58%)	120 (51%)	0.089		
Former smoker	1134 (39%)	1023 (38%)	111 (49%)		532 (24%)	466 (23%)	66 (28%)			
Current smoker	680 (25%)	615 (25%)	65 (33%)		375 (18%)	335 (18%)	40 (21%)			
Alcohol drinker (co	oded)									
No	188 (33%)	174 (33%)	14 (39%)	0.5	552 (44%)	484 (43%)	68 (50%)	0.3		
Yes	339 (67%)	317 (67%)	22 (61%)		570 (56%)	506 (57%)	64 (50%)			
Antihyperlipidemic	c medications ((coded)								
No	2269 (91%)	2083 (91%)	186 (91%)	0.9	1984 (95%)	1788 (95%)	196 (91%)	0.037		
Yes	177 (8.7%)	159 (8.7%)	18 (9.2%)		113 (5.2%)	97 (4.8%)	16 (9.3%)			
Antiplatelet medica	ations (coded)									
No	2404 (99%)	2209 (99%)	195 (97%)	0.006	2075 (99%)	1867 (99%)	208 (99%)	0.3		
Yes	42 (1.1%)	33 (1.0%)	9 (2.9%)		22 (0.8%)	18 (0.7%)	4 (1.5%)			
Ankle-brachial Index (Left)	1.16 (1.09, 1.22)	1.16 (1.10, 1.22)	0.88 (0.79, 1.01)	<0.001	1.11 (1.04, 1.18)	1.12 (1.06, 1.19)	0.88 (0.78, 0.94)	<0.001		
Ankle-brachial	1.16 (1.10,	1.16 (1.11,	0.87 (0.75,	<0.001	1.10 (1.03,	1.11 (1.05,	0.86 (0.77,	<0.001		

Index (Right)	1.22)	1.22)	0.97)		1.18)	1.18)	0.90)	
Albumin (g/L)	44.00 (42.00, 46.00)	44.00 (42.00, 46.00)	43.00 (41.00, 44.00)	<0.001	43.0 (41.0, 44.0)	43.0 (41.0, 45.0)	42.0 (39.0, 44.0)	0.001
AST (U/L)	26 (21, 33)	26 (21, 34)	22 (18, 27)	<0.001	19 (15, 25)	19 (15, 25)	18 (16, 23)	0.2
ALT (U/L)	24 (21, 29)	24 (21, 29)	23 (20, 28)	0.059	21 (18, 25)	21 (18, 25)	22 (19, 26)	0.15
Blood urea nitrogen (mmol/L)	5.00 (4.28, 6.10)	5.00 (3.93, 6.07)	6.07 (4.64, 7.14)	<0.001	4.60 (3.57, 5.71)	4.60 (3.57, 5.71)	5.00 (3.90, 6.78)	0.002
Creatinine (μmol/L)	88 (71, 97)	80 (71, 97)	88 (80, 106)	0.018	62 (53, 71)	62 (53, 71)	71 (62, 88)	<0.001
Total Cholesterol (mg/dL)	203 (179, 228)	204 (179, 228)	193 (171, 220)	0.008	207 (184, 235)	207 (183, 235)	211 (188, 238)	0.3
Triacylglycerols (mg/dL)	132 (89, 200)	132 (89, 200)	130 (86, 190)	>0.9	108 (73, 160)	107 (71, 156)	132 (95, 195)	<0.001
LDL (mg/dL)	124 (103, 147)	124 (103, 148)	115 (85, 136)	0.038	122 (101, 145)	122 (101, 145)	119 (97, 143)	0.8
HDL (mg/dL)	44 (37, 54)	44 (37, 54)	44 (37, 52)	0.4	55 (46, 67)	56 (46, 67)	52 (44, 61)	0.006
Fasting plasma glucose (mg/dL)	101 (94, 111)	100 (94, 110)	108 (92, 125)	0.3	95 (90, 104)	95 (90, 103)	102 (96, 115)	<0.001
Insulin (pmol/L)	57 (37, 92)	56 (37, 90)	85 (41, 129)	0.089	48 (33, 80)	47 (32, 77)	99 (46, 130)	0.007
CRP (mg/dL)	0.18 (0.08, 0.37)	0.18 (0.08, 0.37)	0.27 (0.14, 0.44)	<0.001	0.25 (0.10, 0.58)	0.25 (0.10, 0.57)	0.32 (0.15, 0.76)	0.036

Hemoglobin (g/dL)	15.30 (14.70, 16.00)	15.30 (14.70, 16.00)	15.00 (14.10, 15.80)	0.006	13.90 (13.10, 14.50)	13.90 (13.10, 14.50)	13.80 (12.90, 14.70)	>0.9
FIB4 Score	1.14 (0.89, 1.48)	1.13 (0.89, 1.47)	1.28 (1.02, 1.62)	0.002	0.85 (0.63, 1.15)	0.84 (0.62, 1.14)	1.07 (0.80, 1.37)	<0.001
Albumin- creatinine ratio (μg/mg)	0.59 (0.40, 1.06)	0.58 (0.40, 1.01)	1.07 (0.63, 3.09)	<0.001	0.81 (0.54, 1.54)	0.79 (0.54, 1.44)	1.30 (0.70, 2.67)	<0.001
Iron (μM)	16.5 (12.9, 20.8)	16.7 (12.9, 20.9)	15.4 (11.6, 20.4)	0.065	14.1 (10.6, 18.1)	14.3 (10.6, 18.1)	12.9 (10.2, 16.5)	0.025
Ferritin (ng/mL)	142 (93, 223)	142 (93, 223)	120 (81, 197)	0.3	60 (31, 109)	60 (31, 107)	85 (56, 192)	<0.001
TSAT (%)	26 (20, 33)	27 (20, 33)	25 (17, 32)	0.079	22 (16, 29)	22 (16, 29)	20 (16, 28)	0.2
TIBC (μM)	63 (57, 70)	63 (57, 69)	63 (57, 70)	0.8	64 (58, 71)	64 (58, 71)	61 (54, 70)	0.001

Table 2. Demographics of NHANES 1999-2004 participants

The demographics of the NHANES 1999-2004 participants classified by sex and the presence of PAD are shown in Table 2. The ¹N of participants shown are unweighted numbers. For continuous variables, the summary data are shown as Median (Q1, Q3), and for categorical variables as N (%)- survey weights were included in calculating the summary data. P-values as calculated by the Wilcoxon rank-sum test for complex survey samples or chi-squared test with Rao & Scott's second-order correction^C and significant P-values are boldfaced.

BMI: Body Mass Index, HDL: High-Density Lipoprotein, LDL: Low-Density Lipoprotein, HbA1c: Glycated hemoglobin, CRP: High sensitivity C-reactive protein, eGFR: Estimated Glomerular Filtration Rate, TSAT: Transferrin Saturation, TIBC: Total Iron Binding Capacity, AST: Aspartate Aminotransferase, ALT: Alanine Aminotransferase, FIB4 Score: Fibrosis-4 index Score

Table 3	OR	SE	z	P.	95% CI	
			score	Value	Low	High
Intercept	0.001	3.205	-2.338	0.019	0.000	0.297
Ferritin (<48 ng/mL)	0.868	0.896	-0.158	0.875	0.150	5.031
Ferritin (48-96 ng/mL)	0.481	1.478	-0.495	0.621	0.027	8.714
Ferritin (97-168 ng/mL)	0.284	2.034	-0.619	0.536	0.005	15.306
Ferritin (>169 ng/mL)	0.777	1.061	-0.238	0.812	0.097	6.214
Sex:F (ref=M)	0.281	1.053	-1.205	0.228	0.036	2.215
Ferritin (<48 ng/mL)*Females	1.042	1.177	0.035	0.972	0.104	10.471
Ferritin (48-96 ng/mL) *Females	14.593	1.139	2.354	0.019	1.567	135.935
Ferritin (97-168 ng/mL) *Females	171.066	2.501	2.056	0.040	1.270	23034.375
Ferritin (>169 ng/mL) *Females	3.073	1.247	0.900	0.368	0.266	35.427
Former Smoker (ref= Never Smokers)	1.319	0.392	0.706	0.480	0.612	2.844
Current Smoker (ref= Never Smokers)	4.696	0.282	5.487	<0.001	2.703	8.160
Prediabetes (ref=No diabetes)	1.570	0.257	1.754	0.080	0.948	2.600
Diabetes Mellitus (ref=No diabetes)	1.337	0.403	0.720	0.472	0.607	2.945
Non-Hispanic Black (ref: Non-Hispanic White)	1.296	0.398	0.651	0.515	0.594	2.829
Mexican-American (ref: Non-Hispanic White)	1.281	0.311	0.797	0.425	0.697	2.355
Other Ethnicities (ref: Non-Hispanic White)	0.251	0.740	-1.865	0.062	0.059	1.072
CRP	1.810	0.259	2.293	0.022	1.090	3.004
Age	1.095	0.013	7.241	<0.001	1.068	1.122
Creatinine	1.009	0.006	1.448	0.148	0.997	1.021
ACR	0.058	1.987	-1.430	0.153	0.001	2.868
Triacylglycerols	0.997	0.068	-0.039	0.969	0.873	1.140
BMI	1.078	0.162	0.463	0.644	0.785	1.480
HDL	0.751	0.345	-0.831	0.406	0.382	1.476
Hemoglobin	0.897	0.190	-0.574	0.566	0.618	1.301
Antihyperlipidemic medications (ref=No)	1.318	0.546	0.505	0.613	0.452	3.841
AST	1.005	0.013	0.438	0.662	0.981	1.030
ALT	0.988	0.018	-0.647	0.518	0.953	1.024



HEIST-DiC Cohort

Iron biomarkers

- Iron
- Ferritin
- TSAT
- Transferrin

Vascular function markers

- ICAM1
- VCAM1
- Ankle-Brachial Index



NHANES 1999-2004

Iron biomarkers

- Iron
- Ferritin
- TSAT
- TIBC

Vascular function markers

Ankle-Brachial Index





Machine learning & Regression analysis







в